Merck & Co. MRK Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.93B-48.8% | $18.26B+6.6% | $19.04B— | $16.42B— | $17.45B— | ||
| $810M+3.8% | $820M+7.8% | $802M+8.2% | $793M+11.7% | $780M+15.4% | ||
| -$1.8B-30.1% | -$1.67B-33.8% | -$1.46B+6.5% | -$1.65B-10.1% | -$1.38B+17.3% | ||
| —— | $1.09B+347% | $878.5M+86.9% | $667M-4.2% | $455.5M-50.6% | ||
| —— | $1.18B+41.3% | $1.09B+31.7% | $1.01B+22.0% | $921.25M+12.2% | ||
| —— | $110M-39.6% | $128M+208% | $146M+247% | $164M+168% | ||
| —— | -$1.84B+20.9% | -$1.96B-51.0% | -$2.08B-665% | -$2.21B-392% | ||
| —— | $195M+498% | $134M+73.5% | $73M-64.1% | $12M-96.4% | ||
| —— | $137M-86.6% | $358.5M-56.3% | $580M-6.2% | $801.5M+92.6% | ||
| $17.89B-14.3% | $16.47B-23.3% | $17.07B-6.6% | $18.53B+11.0% | $20.88B+41.5% | ||
| $3.78B-1.7% | $4.11B+21.9% | $4.02B+17.3% | $3.81B+7.6% | $3.84B+3.3% | ||
| $18.82B+2,623% | $10.04B— | -$1.34B-200% | -$746M-200% | -$746M-200% | ||
| —— | —— | —— | $1.66B+285% | $1.1B+169% | ||
| -$22.46B-186% | -$13.74B-77.7% | -$3.98B+36.7% | -$7.55B-172% | -$7.85B+40.4% | ||
| $8.23B+3.7% | $8.18B+4.3% | $8.11B+4.8% | $8.03B+5.1% | $7.94B+5.3% | ||
| $4.79B+104% | $5.08B+289% | $4.32B+257% | $3.44B+179% | $2.35B+78.0% | ||
| $1.14B— | $2.5B— | $3.04B— | —— | —— | ||
| $230M+111% | $92M-48.0% | $57M-66.7% | $48M-72.3% | $109M-40.1% | ||
| —— | —— | —— | -$14.75B— | —— | ||
| $388M+38,700% | $563M+292% | $173M-33.5% | $457M+339% | $1M+100% | ||
| —— | —— | —— | —— | —— | ||
| -$473M— | -$562M— | —— | —— | —— | ||
| $3.13B+24.1% | $2.79B+16.6% | $2.5B+14.3% | $2.51B+18.7% | $2.52B+27.6% | ||
| $3.12B+49.1% | $3.05B+44.7% | $2.07B-0.5% | $2.1B+5.6% | $2.1B+10.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | $110M-39.6% | $128M+208% | $146M+247% | $164M+168% | ||
| —— | —— | —— | —— | —— | ||
| -$473M— | -$562M— | —— | —— | —— | ||
| $8.54B+205% | $0-100% | $700M-94.6% | $2.8B— | $2.8B— | ||
| $109M— | $63M— | -$52M— | —— | —— | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | —— | —— | -$328M-5.5% | -$354M-8.9% | ||
| —— | —— | —— | —— | —— | ||
| $14.12B-17.2% | $12.36B-31.7% | $13.05B-16.3% | $14.72B+6.0% | $17.04B+44.6% | ||
| $14.12B-17.2% | $12.36B-31.7% | $13.05B-16.3% | $14.72B+6.0% | $17.04B+44.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Merck & Co. generate?
- Merck & Co. (MRK) generated $17.9B in operating cash flow over the trailing twelve months.
- What is Merck & Co.'s free cash flow?
- After $3.8B of capital expenditures, Merck & Co.'s free cash flow was $14.1B over the trailing twelve months, down 17.2% year over year.
- Where does Merck & Co.'s cash flow data come from?
- Every line is extracted from Merck & Co.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
